India, May 14 -- Pharma major Roche on Thursday announced the launch of the immunotherapy drug Tecentriq that can, for the first time, be administered subcutaneously, reducing drug delivery time to seven minutes compared to conventional intravenous infusions, which take at least a couple of hours.

"By reducing treatment administration time to approximately seven minutes, Tecentriq SC is a breakthrough innovation that has the potential to dramatically improve the cancer treatment experience of patients - reducing treatment time by 80%," Roche India said in a statement.

Lung cancer is one of the most common cancers in India, with about 80,000 cases diagnosed annually.

Doctors say immunotherapy has been a game changer in cancer treatment,...